The combination of cobimetinib plus atezolizumab did not improve the mPFS compared with pembrolizumab in patients with advanced melanoma, and no differences were found in the prognosis and treatment efficacy of NF1 mutations, NRAS mutations (mPFS: 5.5 months of combination group and 5.7 months of pembrolizumab group), or other mutations in both groups [511]. This evidence concerns the gene NRAS and melanoma.